Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743636 · ClinicalTrials.gov registry record · Phase 3
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT03743636: Completed Phase 3 study, sponsored by Northwestern University.
NCT03743636 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03743636, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than placebo and whether NR combined with resveratrol significantly improves walking performance more than placebo. If findings support the hypotheses, results will be used to design a large, definitive randomized clinical. The study will randomize 90 participants with PAD to one of the following three groups: NR + resveratrol, NR + placebo, or placebo + placebo.
Primary Outcome
Among participants with PAD, investigators will determine whether NR alone improves six-minute walk distance at 6-month follow-up, compared to placebo.
Interventions
- OTHER Placebo
- DRUG Nicotinamide riboside
- DRUG Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 3 |
What the finished NCT03743636 record still lists
NCT03743636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03743636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03743636 about?
NCT03743636 is a clinical study titled "Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease". NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than placebo and whether NR combined with resveratrol significantly improves wa...
What is the current status of trial NCT03743636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2018-10-01. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT03743636?
The interventions under investigation include: Placebo (OTHER), Nicotinamide riboside (DRUG), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT03743636?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03743636's enrollment target sits among peer trials
90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI